A 38-year-old man with a 2-year history of Meniere disease (confirmed by classic presentation and audiometry) presents with worsening vertigo attacks occurring 2–3 times per week, despite 6 months of salt restriction and hydrochlorothiazide therapy. Audiometry shows progressive low-frequency hearing loss bilaterally. He reports severe functional impairment. Which of the following is the most appropriate next step in management?

Explanation

## Management of Refractory Meniere Disease ### Treatment Algorithm ```mermaid flowchart TD A["Meniere Disease Diagnosed"]:::outcome --> B["First-line: Salt restriction,<br/>diuretics, betahistine"]:::action B --> C{"Response to<br/>medical therapy?"}:::decision C -->|"Yes"| D["Continue maintenance<br/>therapy"]:::action C -->|"No (refractory)"| E["Intratympanic therapy:<br/>Dexamethasone or Gentamicin"]:::action E --> F{"Vertigo controlled?"}:::decision F -->|"Yes"| G["Continue monitoring"]:::action F -->|"No"| H["Surgical options:<br/>Endolymphatic sac surgery,<br/>vestibular nerve section,<br/>labyrinthectomy"]:::action H --> I["Consider cochlear implant<br/>if severe bilateral SNHL"]:::action ``` ### Why Intratympanic Therapy is Appropriate Here **Key Point:** This patient has **refractory Meniere disease** (inadequate response to medical therapy after 6 months) with significant functional impairment. Intratympanic therapy is the **evidence-based next step** before surgical intervention. ### Intratympanic Therapy Options | Agent | Mechanism | Efficacy | Side Effects | Notes | |-------|-----------|----------|--------------|-------| | **Dexamethasone** | Anti-inflammatory | 50–70% vertigo control | Minimal systemic | Preserves hearing; preferred first-line intratympanic | | **Gentamicin** | Ototoxic aminoglycoside | 70–90% vertigo control | Hearing loss risk (30–50%) | Effective but irreversible; reserved for refractory cases | | **Betahistine (oral)** | Vasodilator, H3-antagonist | 40–60% | Minimal | Already tried (implied in medical therapy) | **High-Yield:** Intratympanic dexamethasone or gentamicin are **minimally invasive, reversible (dexamethasone) or semi-reversible (gentamicin), and highly effective** for vertigo control in refractory Meniere disease. They avoid the morbidity of major surgery. ### Why Each Alternative is Premature or Incorrect **Increasing diuretics:** Already on appropriate medical therapy; escalation without intratympanic intervention skips the evidence-based stepwise approach. **Endolymphatic sac surgery:** Surgical intervention is reserved for **failure of intratympanic therapy**. It is more invasive and has variable efficacy (50–70%). Intratympanic therapy should be attempted first. **Cochlear implant:** Indicated only for **severe bilateral SNHL with poor speech discrimination**. This patient has unilateral disease (implied) and does not yet meet criteria. Implant is not a vertigo treatment. ### Intratympanic Dexamethasone Protocol - **Dose:** 0.4 mL of 4 mg/mL solution (1.6 mg total) injected into middle ear via myringotomy or tympanostomy tube - **Frequency:** Weekly injections × 4 weeks - **Timing:** Injected under otoscopic guidance; patient remains supine 30 minutes to allow diffusion - **Outcome:** Vertigo control in 50–70%; hearing preservation in most **Clinical Pearl:** Intratympanic therapy achieves **direct drug delivery to the inner ear** without systemic absorption, maximizing efficacy and minimizing side effects. ### Surgical Options (if Intratympanic Fails) 1. **Endolymphatic sac decompression** — reduces hydrops; 50–70% effective 2. **Vestibular nerve section** — eliminates vertigo; preserves hearing 3. **Labyrinthectomy** — eliminates vertigo and hearing (only if hearing already lost) [cite:Dhingra 8e Ch 5; Cummings Otolaryngology 7e Ch 165]